Ketamine: all studies (page 326) - The Consciousness Library

Predicting Cardiovascular Collapse in Critically Ill Patients During Intubation Induction: A Prospective Observational Study.

Medicina (Kaunas, Lithuania) January 15, 2026 Ömer Emgin, Gamze Taşkan, Aytuğ Yıldız et al.

Background and Objectives: The study aimed to evaluate the predictive significance of Shock Indices and induction agents in predicting the risk of Peri-Intubation Cardiovascular Collapse (PIC) during intubation in the ICU. Materials and Methods: A total of 130 patients were analyzed in the study after dividing them into 2 groups based on the definition of PIC as Patients with PIC and Non-PIC...

DOI: 10.3390/medicina62010177 Full text Ketamine Intensive care unit Peri-intubation cardiovascular collapse Propofol +1

Rethinking the Treatment-Resistant Depression.

Advances in experimental medicine and biology 2026 Yunfei Tan, Kenji Hashimoto 1 citation

Treatment-resistant depression (TRD) affects about one-third of people with major depression and leads to higher suicide rates, impaired functioning, and increased healthcare use. Originally defined as nonresponse to tricyclic antidepressants, TRD now encompasses inadequate response to multiple antidepressant classes, psychotherapy, and neuromodulation. Inconsistent criteria-varying by agency,...

DOI: 10.1007/978-981-95-6872-7_5 Full text Ketamine Biomarkers Individualized treatment Inflammation +2

Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker.

Journal of Neuroendocrinology 2026 Hiroe Hu, Yoojin Lee, Alaina N Tillman et al. 1 citation

Arginine vasopressin (AVP) modulates stress responsivity and social-affective behaviors, but its role in mood and trauma-related disorders remains poorly defined due to challenges in peripheral measurement. This study used copeptin, a stable, reliable, and well-validated surrogate marker of AVP secretion, to assess vasopressinergic function in a transdiagnostic sample of individuals...

DOI: 10.1111/jne.70133 Full text PTSD Depression Ketamine Copeptin +1

Psychedelics: Future Therapeutics in Major Depression?

Advances in experimental medicine and biology 2026 Berend Olivier, Jocelien D A Olivier

Major depressive disorder (MDD), including treatment-resistant depression (TRD), is a highly prevalent psychiatric disorder. MDD is associated with severe suffering, burden and large economical costs. Although various conventional antidepressant treatments are available, a large portion of depressed people does not or not adequately respond to the first-line treatments (mostly SSRIs and SNRIs)...

DOI: 10.1007/978-981-95-6872-7_25 Full text Ayahuasca Ketamine Major depressive disorder Psilocybin +11

Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics".

Global Advances in Integrative Medicine and Health 2026 Haley D M Schuman, Raèf Mina, Sofia Barkova et al.

Healthcare providers' (HCPs) perspectives on psychedelic-assisted therapy (PAT) are critical to clinical integration but remain underexplored in Canadian palliative and oncology contexts. This study examines HCP attitudes toward ketamine, psilocybin, and MDMA, and the systemic and ethical factors influencing implementation. An exploratory qualitative study using semi-structured interviews was...

DOI: 10.1177/27536130261459354 Full text MDMA Ketamine Psilocybin Cancer +2

Adenosine as the metabolic common path of rapid antidepressant action: The coffee paradox.

Brain medicine December 31, 2025 Julio Licinio, Ma-Li Wong 3 citations

Yue, Luo, and colleagues discovered that adenosine signalling is the common underlying mechanism of rapid acting antidepressant therapies, unifying the effects of ketamine, ECT and acute intermittent hypoxia. They use genetically encoded sensors, along with extensive mechanistic dissection, to show that all three induce adenosine surges in mood-regulatory circuits via A1 and A2A receptor...

DOI: 10.61373/bm025c.0134 Full text Depression Ketamine Adenosine Antidepressants +2

A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder

Current Treatment Options in Psychiatry December 26, 2025 Manasicha P. Wongpaiboon, Jackson L. Shelton, Eric Delgado Rendon et al.

Purpose A systematic review was conducted to synthesize the efficacy, safety, and tolerability of psychedelics including ketamine, MDMA, ayahuasca, LSD, DMT, ibogaine, and psilocybin in the treatment of PTSD. Recent Findings Among 5,155 studies identified, 42 studies met criteria and were included in our systematic review. Ketamine consistently produced rapid symptom improvement that attenuated...

DOI: 10.1007/s40501-025-00373-w Full text Ketamine Psilocybin Hallucinogens 3,4-methylenedioxymethamphetamine +1

Synaptic priming: A framework for pharmacotherapy in depression.

Neuron November 19, 2025 Kyle A Brown, Musa I Ajibola, Gustavo C Medeiros et al. 6 citations

Recent antidepressant drug development focuses on a next generation of drugs to rapidly relieve symptoms. Yet, how ketamine, the prototype rapid-acting antidepressant, maintains symptom relief days after drug elimination, and how repeated doses sustain longer-lasting therapeutic effects, remains unclear. Derived from elements of metaplasticity (synaptic priming), this review discusses a...

DOI: 10.1016/j.neuron.2025.09.010 Full text Depression Ketamine Neuroplasticity Bcm +8

The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample.

Journal of Psychoactive Drugs November 9, 2025 James M Zech, Jérémie Richard, Grant Jones

Psychedelic-assisted interventions are emerging as potential treatments for substance use disorders, including alcohol use disorder (AUD). While recent randomized controlled trials suggest efficacy for certain psychedelics and related compounds in treating AUD, the impact of naturalistic psychedelic use on problematic alcohol consumption remains underexplored. This study examines associations...

DOI: 10.1080/02791072.2025.2583967 Full text LSD MDMA Ketamine Psilocybin +2

Is poor dose selection undermining the translational validity of antidepressant research involving animal models?

bioRxiv (Cold Spring Harbor Laboratory) November 1, 2025 Dasha Anderson, Justyna K. Hinchcliffe, Megan N. Jackson et al. 1 citation preprint

Abstract Background Behavioural studies in animal models represent a critical component of psychiatric drug development. Positive results in animal studies have identified novel therapeutic targets for major depressive disorder (MDD) but efficacy in humans has largely not been borne out in clinical trials. A possible reason for this failed translation is inappropriate dose selection and the...

DOI: 10.1101/2025.10.25.684561 Major depressive disorder Ketamine Treatment-resistant depression Antidepressant +15

Research